eXoZymes (EXOZ) Stock Price, News & Analysis

Company Overview

eXoZymes, Inc. develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide. Headquartered in the United States, the company distributes its products through direct sales and a global network of distributors, positioning itself to support growth in both research and diagnostic markets.

Key Stats

• Today's Range: $6.85 to $7.10
• 50-Day Range: $4.40 to $8.49
• 52-Week Range: $4.35 to $18.40
• Volume: 1,306 shs
• Average Volume: 4,364 shs
• Market Capitalization: $63.26 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

eXoZymes Stock Analysis - MarketRank™

eXoZymes scored higher than 30% of companies evaluated by MarketBeat, and ranked 765th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

eXoZymes has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

eXoZymes has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of eXoZymes is -5.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of eXoZymes is -5.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

eXoZymes has a P/B Ratio of 17.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.76% of the float of eXoZymes has been sold short.

Short Interest Ratio / Days to Cover

eXoZymes has a short interest ratio ("days to cover") of 3.67, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in eXoZymes has recently decreased by 10.85%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

eXoZymes does not currently pay a dividend.

Dividend Growth

eXoZymes does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.00

News Sentiment

eXoZymes has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for eXoZymes this week, compared to 1 article on an average week.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $6,406.00 in company stock, which represents 0.0101% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, eXoZymes insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,406.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

72.41% of the stock of eXoZymes is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

eXoZymes has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EXOZ
• CIK: 2010788
• Web: exozymes.com
• Phone: (626) 415-1488
• Fax: N/A
• Employees: 29
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -292.15%
• Return on Assets: -158.66%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 3.81
• Quick Ratio: 3.81

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.39 per share
• Price / Book: 17.48

Miscellaneous

• Outstanding Shares: 9,281,000
• Free Float: 2,561,000
• Market Cap: $63.26 million
• Optionable: N/A
• Beta: 3.14